tamer abd elwahab abd elmonem mohamed diab
Lecturer
Does preoperative silodosin administration facilitate ureteral dilatation during fexible ureterorenoscopy? A randomized clinical trial
• 2023
Publication Information
Authors
Tamer Diab1 · Waleed El‑Shaer1
· Saad Ibrahim1
· Ehab El‑Barky1
· Ahmed Abou Elezz1
Keywords
Not Available
Journal
Not Available
Publisher
Not Available
Volume
Not Available
Issue
Not Available
Pages
Not Available
publication.type
International
Paper Link
Not Available
Supplementary Materials
Not Available
Abstract
Purpose To assess whether preoperative administration of silodosin can facilitate the placement of ureteral access sheath
(UAS) prior to fexible ureteroscopy (F-URS) and reduce the occurrence of ureteric injury in challenging cases.
Methods This prospective randomized clinical trial was carried out on 147 patients diagnosed with upper ureteric stone or
stone kidney, non-stented. The patients were randomly divided into two equal groups. Group A (silodosin group) included
patients in whom F-URS was done with daily preoperative intake of 8 mg silodosin for 1 week and group B (placebo/control
group) included patients in whom F-URS was done with daily preoperative intake of placebo tablets.
Results In group A, a total of 23 (33.3%) experienced ureteral wall injury following UAS insertion, while in group B, this
occurred in 40 patients (59.7%). There was a statistically signifcant diference in the grade of ureteral wall injury between
the two groups (P
(UAS) prior to fexible ureteroscopy (F-URS) and reduce the occurrence of ureteric injury in challenging cases.
Methods This prospective randomized clinical trial was carried out on 147 patients diagnosed with upper ureteric stone or
stone kidney, non-stented. The patients were randomly divided into two equal groups. Group A (silodosin group) included
patients in whom F-URS was done with daily preoperative intake of 8 mg silodosin for 1 week and group B (placebo/control
group) included patients in whom F-URS was done with daily preoperative intake of placebo tablets.
Results In group A, a total of 23 (33.3%) experienced ureteral wall injury following UAS insertion, while in group B, this
occurred in 40 patients (59.7%). There was a statistically signifcant diference in the grade of ureteral wall injury between
the two groups (P